These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 11060723)
41. Technology evaluation: HIV ribozyme gene therapy, Gene Shears Pty Ltd. de Feyter R; Li P Curr Opin Mol Ther; 2000 Jun; 2(3):332-5. PubMed ID: 11249628 [TBL] [Abstract][Full Text] [Related]
42. Ribozymes and the anti-gene therapy: how a catalytic RNA can be used to inhibit gene function. Muotri AR; da Veiga Pereira L; dos Reis Vasques L; Menck CF Gene; 1999 Sep; 237(2):303-10. PubMed ID: 10521654 [TBL] [Abstract][Full Text] [Related]
43. Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus. Ohkawa J; Yuyama N; Takebe Y; Nishikawa S; Taira K Proc Natl Acad Sci U S A; 1993 Dec; 90(23):11302-6. PubMed ID: 8248243 [TBL] [Abstract][Full Text] [Related]
44. [Specific inhibition of anti-DNA antibody production by an anti-DH ribozyme]. Suzuki Y; Funato T Nihon Rinsho; 1997 Jun; 55(6):1557-61. PubMed ID: 9200948 [TBL] [Abstract][Full Text] [Related]
45. Ribozymes: structure, function, and potential therapy for dominant genetic disorders. Grassi G; Marini JC Ann Med; 1996 Dec; 28(6):499-510. PubMed ID: 9017109 [TBL] [Abstract][Full Text] [Related]
46. A ribozyme targeted to RNA polymerase gene of infectious bursal disease virus effectively cleaves and inhibits expression of the viral gene product. Akin A; Lin TL; Wu CC Acta Virol; 1999 Dec; 43(6):341-7. PubMed ID: 10825922 [TBL] [Abstract][Full Text] [Related]
47. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Hudson AJ; Normand N; Ackroyd J; Akhtar S Int J Pharm; 1999 May; 182(1):49-58. PubMed ID: 10332074 [TBL] [Abstract][Full Text] [Related]
49. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Ngok FK; Mitsuyasu RT; Macpherson JL; Boyd MP; Symonds GP; Amado RG Methods Mol Biol; 2004; 252():581-98. PubMed ID: 15017082 [TBL] [Abstract][Full Text] [Related]
50. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Sun LQ; Wang L; Gerlach WL; Symonds G Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887 [TBL] [Abstract][Full Text] [Related]
51. Ribozymes: structure, characteristics and use as potential antiviral agents. Bartolomé J; Madejón A; Carreño V J Hepatol; 1995; 22(1 Suppl):57-64. PubMed ID: 7602079 [TBL] [Abstract][Full Text] [Related]
52. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes. Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986 [TBL] [Abstract][Full Text] [Related]
54. Ribozyme mediated destruction of influenza A virus in vitro and in vivo. Tang XB; Hobom G; Luo D J Med Virol; 1994 Apr; 42(4):385-95. PubMed ID: 8046429 [TBL] [Abstract][Full Text] [Related]
55. Interaction between tumour necrosis factor alpha ribozyme and cellular proteins. Involvement in ribozyme stability and activity. Sioud M J Mol Biol; 1994 Oct; 242(5):619-29. PubMed ID: 7932719 [TBL] [Abstract][Full Text] [Related]
56. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III. Denman RB; Smedman M; Kung L Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076 [TBL] [Abstract][Full Text] [Related]